(Q46791880)

25 December 2017

title

Something old, something new: beta blockers and clopidogrel in acute myocardial infarction (English)

1 reference

25 December 2017

1 reference

myocardial infarction

1 reference

Marc S Sabatine

1

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

25 December 2017

published in

The Lancet

1 reference

25 December 2017

volume

366

1 reference

25 December 2017

issue

9497

1 reference

25 December 2017

page(s)

1587-1589

1 reference

25 December 2017

Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Effect of propranolol in myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Management of acute myocardial infarction in patients presenting with ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

The open-artery theory is alive and well--again

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Why do we need some large, simple randomized trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967641-6

7 January 2021

10.1016/S0140-6736(05)67641-6

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017